RT Journal Article
SR Electronic
T1 Unraveling the role of plasma proteins in dementia: insights from two cohort studies in the UK, with causal evidence from Mendelian randomization
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.06.04.24308415
DO 10.1101/2024.06.04.24308415
A1 Gong, Jessica
A1 Williams, Dylan M.
A1 Scholes, Shaun
A1 Assaad, Sarah
A1 Bu, Feifei
A1 Hayat, Shabina
A1 Zaninotto, Paola
A1 Steptoe, Andrew
YR 2024
UL http://medrxiv.org/content/early/2024/06/04/2024.06.04.24308415.abstract
AB Population-based proteomics offer a groundbreaking avenue to predict dementia onset. This study employed a proteome-wide, data-driven approach to investigate protein-dementia associations in 229 incident all-cause dementia (ACD) among 3,249 participants from the English Longitudinal Study of Ageing (ELSA) over a median 9.8-year follow-up, then validated in 1,506 incident ACD among 52,745 individuals from the UK Biobank (UKB) over median 13.7 years. NEFL and RPS6KB1 were robustly associated with incident ACD; MMP12 was associated with vascular dementia in ELSA. Additional markers EDA2R and KIM1 (HAVCR1) were identified from sensitivity analyses. Combining NEFL and RPS6KB1 with other factors yielded high predictive accuracy (area under the curve (AUC)=0.871) for incident ACD. Replication in the UKB confirmed associations between identified proteins with various dementia subtypes. Results from reverse Mendelian Randomization also supported the role of several proteins as early dementia biomarkers. These findings underscore proteomics’ potential in identifying novel risk screening targets for dementia.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe National Institute of Aging (NIA) (grant No. [R01AG17644]) funded the proteomics data curation in ELSA. J.G. is supported by the NIA (grant No. [R01AG17644]). D.M.W. is supported by the British Medical Research Council (MRC) (grant No. [MC_UU_00019/3]). This research has been conducted using the UK Biobank Resource under application number 71702. This work uses data provided by patients and collected by the NHS as part of their care and support. Copyright 2023, NHS England. Re-used with the permission of the NHS England and UK Biobank. All rights reserved.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical consent has been obtained for all waves and components of ELSA, by the National Research Ethics Service. UK Biobank has approval from the North West Multi-centre Research Ethics Committee (MREC) as a Research Tissue Bank (RTB) approval.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes